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Abstract
In a small percentage of patients with immune thrombocytopenia (ITP), H. pylori eradication has
a positive effect on platelet counts. Whether H. pylori infection is associated with a lower
thrombocyte count in persons without clinical ITP is unknown. We performed a cross-sectional
study to compare thrombocyte count between H. pylori infected (n¼ 108) and H. pylori
non-infected patients (n¼ 600) who underwent a diagnostic gastroscopy. The mean
thrombocyte count in H. pylori negative patients was 257 109/l, in H. pylori positive patients
252 109/l (mean difference 5 109/l, 95% CI: 23 to 14). Subgroup analysis did not show
significant differences either. In the patient group without apparent comorbidity, there were no
subjects with thrombocyte counts 5120. In 36 H. pylori positive patients in whom data post-
eradication was available, platelet counts pre- and post-eradication were similar. In conclusion,
this study could not demonstrate a lower thrombocyte count in H. pylori infected patients or in
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Introduction
In a small percentage of immune thrombocytopenia (ITP) patients
infected with H. pylori, eradication of the bacteria has a positive
effect on platelet counts [1, 2]. The pathogenesis of this
phenomenon is not entirely clear. Hypothesized pathophysio-
logical mechanisms for thrombocytopenia related to H. pylori
infection are mainly immunological, such as stimulation of
autoreactive B-cell clones, and cross-mimicry between epitopes
of glycoproteins on thrombocytes and antigens against H. pylori
[3]. Host-mediated factors such as human leukocyte antigen
patterns have also been mentioned [4]. Despite an adequate
inflammatory response, H. pylori infection usually persists for life
without antibiotic intervention [5]. If an effect of H. pylori on
thrombocytes exist, the low grade inflammatory response that
remains present during life [6], might lead to a lower thrombocyte
count even in the absence of ITP.
H. pylori infection is highly prevalent; in developing countries,
nearly everyone is infected by the age of 50 years. [5] Prevalence
in developed countries is decreasing rapidly due to effective
treatment. ITP on the other hand has an annual incidence of
11/1 000 000 [7]. Thus, although H. pylori infection is not a
sufficient cause for thrombocytopenia, among H. pylori infected
persons subgroups may be identifiable in whom thrombocyto-
penia occurs. The identification of these groups would aid in the
understanding of the pathophysiological route to thrombocyto-
penia in H. pylori infected patients.
We compared thrombocyte counts between H. pylori infected
and H. pylori non-infected patients who underwent a diagnostic
gastroscopy. We hypothesized that a lower thrombocyte count
might be found in H. pylori infected patients or in subgroups of
H. pylori infected patients compared to non-infected subjects.
Design and methods
Study design
We performed a cross-sectional study to compare thrombocyte
count between H. pylori infected and H. pylori non-infected
patients. Charts of all patients who underwent a diagnostic
gastroscopy from 1 January 2010 to 31 December 2011 in the
Leiden University Medical Center, a tertiary teaching hospital,
were reviewed for H. pylori status: thrombocyte count, white
blood cell count and hemoglobin.
Patients
All patients in whom a biopsy and cultures for H. pylori were
taken were included in the study, regardless of disease type or
indication for gastroscopy. Patients were defined H. pylori
positive when either the light microscopy or the tissue cultures
proved to be positive.
We abstracted the presence of underlying diseases with known
effect on thrombocyte count (malignancies, alcohol abuse,
autoimmune diseases, hepatitis B, hepatitis C, HIV, liver cirrhosis
and liver transplant patients) and diseases without known effect
on thrombocyte count (iron deficiency/anemia, upper abdominal
complaints, miscellaneous) based on a review of charts from
patients included for study. This miscellaneous group is
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heterogeneous and consisted of patients who underwent gastros-
copy for screening for malignancy, people with venous throm-
bosis and unexplained weight loss as well as constipation and
screening for suspected celiac sprue.
Laboratory analysis
All cell counts (thrombocytes, leucocytes and hemoglobin) were
performed for routine medical practice purposes with an
automated cell counter (XE-2100, Sysmex, Sysmex
Corporation, Kobe, Japan). For all patients, the thrombocyte
count closest to the gastroscopy was extracted, preferably at day
of the procedure. Since H. pylori is a chronic infection, blood cell
counts were taken into account up to 1 year before gastroscopy,
assuming that the infection was contracted well before gastros-
copy and thus a possible effect would have started earlier.
If available, for infected patients, thrombocyte count post-
eradication was noted. We used the first thrombocyte count
available at least 3 weeks but no longer than 1 year after
eradication therapy. The time limit of 3 weeks was chosen
because response time after therapy is estimated 2 weeks [8], plus
one week for completing the 7-day regimen.
Diagnostic procedures
In all patients, gastroscopy was performed for various clinical
indications. No patients underwent gastroscopy for study reasons.
Standard procedures included two biopsies for pathology analysis
and one biopsy for tissue culturing from the antrum, as well as a
similar procedure in the corpus, using a standard gastric biopsy
forceps (Radial Jaw, Boston Scientific, Natlick, USA). Light
microscopy was used to confirm presence of H. pylori. In case of
doubt, additional immunohistochemical dyeing was performed.
Biopsies were cultured for H. pylori.
Statistical analysis
Differences in platelet count, hemoglobin and white blood cell
count between H. pylori infected and non-infected subjects were
tested in a linear regression model. Sub-analyses were performed
stratified by underlying disease categories as described earlier.
Differences in platelet count pre- and post-eradication were
analyzed using a paired t-test. Analyses were adjusted for age and
sex. p value 50.05 was considered statistically significant.
Analyses were performed using STATA Statistical Software
(StataCorp 2011, Release 12; College Station, TX: StataCorp LP).
Results and discussion
In total, 899 patients underwent a diagnostic gastroscopy with
biopsies for H. pylori examination between 2010 and 2011. Of
these patients, 191 could not be included because thrombocyte
counts were not routinely measured. Details of 708 included
patients are shown in Table I. The mean age was 53 years, 55%
were women. Patients with upper abdominal complaints com-
prised the largest group (45%). Of the included patients, 600 were
H. pylori negative and 108 H. pylori positive. Men were more
often H. pylori positive than women (19 vs. 12%, respectively). In
total, 20 patients in the H. pylori negative group had platelet
counts under 100 109/l, with a mean platelet count of 77 109/l
(95% CI: 67–87). Of all H. pylori infected patients, three had
platelet counts under 100 109/1 with a mean platelet count of
61 10 109/l (95% CI: 13–109).
The mean thrombocyte count in H. pylori negative patients
was 257 109/l, in H. pylori infected patients the mean
thrombocyte count was 252 10 109/l, mean difference
5 109/l, (95% CI: 23 to 14). Mean platelet counts in H.
pylori positive patients were thus not different from mean platelet
counts in H. pylori negative patients. Stratified by underlying
disease/indication for gastroscopy, also no clearly lower thrombo-
cyte count could be shown in H. pylori positive patients (Table II).
Thrombocyte counts ranged from 18 109/l to 789 109/l in
the disease categories that are known to have an effect
on thrombocyte count (specified previously). In the disease
categories without known effect on thrombocyte count, thrombo-
cyte count ranged from 110 109/l to 726 109/l. The last,
miscellaneous group, ranges were 69 109/l–1059 109/l
thrombocytes.
Mean difference in white blood cell count was 0.3 109/l
(95% CI: 0.9 to 0.9) and mean difference in hemoglobin was
0.3 mM/l (95% CI: 1.0 to 0.4), also showing no difference
between H. pylori infected and H. pylori uninfected patients.
All H. pylori positive patients underwent eradication therapy
with mostly culture-directed therapy (if feasible). Of the 36
H. pylori positive patients in whom thrombocyte counts
post-eradication were available, platelet counts pre- and post-
eradication were 234 109/l and 238 109/l, respectively, mean
difference of 5 (95% CI: 22 to 14).
In the present cross-sectional study including 708 consecutive
patients tested for H. pylori infection after gastroscopy, we did not
find a clear association between thrombocyte count and H. pylori
status. Also stratified by underlying disease/indication for
gastroscopy, no clearly lower thrombocyte count could be
shown in H. pylori positive patients.
Our primary hypothesis was that H. pylori infection might be
associated with a lower thrombocyte count, even if the effect
might be small. This hypothesis would have supported the idea of
an ongoing H. pylori-mediated low inflammatory response
leading to lower thrombocyte counts. One of the factors that
may influence the appearance of thrombocytopenia in the
presence of H. pylori infection is the presence of the CagA
mutation carrying H. pylori strains. However, in this cohort, we
have not been able to evaluate such an effect. Our study had a
power of 0.95 for detecting a difference of 35 109 in thrombo-
cyte count with a p value of 0.05. A small effect might therefore
been missed.
There are many reports about the link between H. pylori
infection and ITP. In this cross-sectional study, none of the
H. pylori positive patients had thrombocyte counts in the range







Total 708 600 108
Male 316 (45) 255 61




Age (mean, in years) 53 53 53
Disease type
Iron deficiency/anemia 73 (10) 59 14
Malignancy 50 (7) 44 6
Miscellaneous 135 (19) 112 25
Alcohol 6 (1) 5 1
Autoimmune* 69 (10) 63 6
Hepatitis B 6 5 1
Hepatitis C 5 3 2
Transplant recipient** 26 (4) 24 2
Liver disease 15 (2) 10 3
Upper abdominal complaints 317 (45) 271 46
*Patients with celiac disease, imflammatory bowel disease and auto-
immune hepatitis. There were no patients in this cohort with ITP.
**Most were kidney transplant patients, a few (510) patients with a liver
transplant were included.



















































compatible with a diagnosis of ITP. Although this might suggest
that the absolute risk for H. pylori-associated ITP is very low, also
selection presumably plays a role, since patients with very low
thrombocyte counts might not undergo a gastroscopy with
biopsies unless the indication is life threatening.
In our study, men were more often H. pylori positive than
women, most notable in the group with upper abdominal
complaints. Although this study was not designed to demonstrate
a gender difference in H. pylori infection rate, population-based
studies and meta-analyses have demonstrated a similar results
[9, 10]. So far, the reason for this difference has only been
speculated upon.
Our sample was taken from patients mostly with gastrointes-
tinal complaints in a tertiary referral center. Because the
prevalence of H. pylori infection (15%) did not differ materially
from the prevalence in the general population in a recent study in
a neighboring country (Belgium), and is a little higher than that
reported in a recent large cohort study from the USA [11, 12], our
results seem generalizable to the general population.
In conclusion, we could not demonstrate a lower thrombocyte
count in H. pylori infected patients compared to non-infected
subjects. The lack of association between platelet count and
H. pylori infection in this cohort suggests that the reported
association between H. pylori and thrombocytopenia is an all or
nothing phenomenon that occurs in a small subgroup of patients,
if it occurs at all. Since our cohort had relatively few patients with
thrombocyte counts 5100109, no substantiated conclusion can
be drawn.
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Total population 257 252 5 (23 to 14)
Iron deficiency/anemia 272 266 2(64 to 59)
Malignancy 222 186 32(117 to 52)
Miscellaneous 272 289 18(31 to 66)
Alcohol 249 166 83(387 to 222)
Autoimmune 272 254 18(105 to 67)
Hepatitis B 238 134 104(not measurable)
Hepatitis C 179 150 29(129 to 249)
HIV 192 224 33(151 to 86)
Transplant 205 340 133(7 to 272)
Liver disease 129 146 5(97 to 87)
Upper abdominal complaints 260 253 1,6(21 to 18)
*Mean difference adjusted for age and sex.
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